126 related articles for article (PubMed ID: 16303720)
1. Prostate cancer with small-cell morphology: an immunophenotypic subdivision.
Petraki C; Vaslamatzis M; Petraki K; Revelos K; Alevizopoulos N; Papanastasiou P; Gregorakis A
Scand J Urol Nephrol; 2005; 39(6):455-63. PubMed ID: 16303720
[TBL] [Abstract][Full Text] [Related]
2. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
3. Changes in tissue prostatic acidic phosphatase during endocrine treatment of patients with prostatic carcinoma.
Grande M; Carlström K; Lundh-Rozell B; Stege R; Pousette A
Scand J Urol Nephrol; 2005; 39(5):393-8. PubMed ID: 16257841
[TBL] [Abstract][Full Text] [Related]
4. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
5. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract.
Helpap B
Cancer; 2002 Oct; 95(7):1415-20. PubMed ID: 12237909
[TBL] [Abstract][Full Text] [Related]
6. Predictors of outcome in small cell carcinoma of the cervix--a case series.
Straughn JM; Richter HE; Conner MG; Meleth S; Barnes MN
Gynecol Oncol; 2001 Nov; 83(2):216-20. PubMed ID: 11606074
[TBL] [Abstract][Full Text] [Related]
7. Serum calcitonin in small cell carcinoma of the prostate.
Sim SJ; Glassman AB; Ro JY; Lee JJ; Logothetis CJ; Liu FJ
Ann Clin Lab Sci; 1996; 26(6):487-95. PubMed ID: 8908318
[TBL] [Abstract][Full Text] [Related]
8. Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome?
Yamada Y; Nakamura K; Aoki S; Taki T; Matsubara H; Sai S; Naruse K; Tobiume M; Katsuda R; Zennami K; Honda N; Nakagawa A; Ikeda H
Oncol Rep; 2006 May; 15(5):1309-13. PubMed ID: 16596203
[TBL] [Abstract][Full Text] [Related]
9. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
10. Morphological features correlation with serum tumour markers in prostatic carcinoma.
Afzal S; Ahmad M; Mushtaq S; Mubarik A; Qureshi AH; Khan SA
J Coll Physicians Surg Pak; 2003 Sep; 13(9):511-4. PubMed ID: 12971871
[TBL] [Abstract][Full Text] [Related]
11. Prostatic adenocarcinoma metastases mimicking small cell carcinoma on fine-needle aspiration.
Parwani AV; Ali SZ
Diagn Cytopathol; 2002 Aug; 27(2):75-9. PubMed ID: 12203872
[TBL] [Abstract][Full Text] [Related]
12. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
[TBL] [Abstract][Full Text] [Related]
13. Liver metastases in prostate carcinoma: clinical characteristics and outcome.
Pouessel D; Gallet B; Bibeau F; Avancès C; Iborra F; Sénesse P; Culine S
BJU Int; 2007 Apr; 99(4):807-11. PubMed ID: 17155968
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
15. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S
Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344
[TBL] [Abstract][Full Text] [Related]
16. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
17. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
[TBL] [Abstract][Full Text] [Related]
20. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.
Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T
Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
